| Primary |
| Multiple Sclerosis |
90.9% |
| Relapsing-remitting Multiple Sclerosis |
2.9% |
| Depression |
1.0% |
| Hypertension |
0.8% |
| Pain |
0.8% |
| Hypothyroidism |
0.3% |
| Product Used For Unknown Indication |
0.3% |
| Contraception |
0.3% |
| Neuralgia |
0.3% |
| Insomnia |
0.3% |
| Anxiety |
0.3% |
| Convulsion |
0.2% |
| Ms |
0.2% |
| Vitamin Supplementation |
0.2% |
| Diabetes Mellitus |
0.2% |
| Multiple Sclerosis Relapse |
0.2% |
| Hypersensitivity |
0.2% |
| Muscle Spasms |
0.2% |
| Sleep Disorder |
0.2% |
| Blood Cholesterol Increased |
0.2% |
|
| Multiple Sclerosis Relapse |
21.8% |
| Urticaria |
9.9% |
| Injection Site Pain |
8.0% |
| Death |
6.4% |
| Convulsion |
4.9% |
| Injection Site Reaction |
4.8% |
| Vomiting |
4.4% |
| Immediate Post-injection Reaction |
3.7% |
| Anaphylactic Reaction |
3.6% |
| Dyspnoea |
3.5% |
| Drug Ineffective |
3.4% |
| Tremor |
3.2% |
| Anaphylactic Shock |
3.1% |
| Injection Site Necrosis |
3.1% |
| Hypersensitivity |
3.0% |
| Pain |
2.7% |
| Breast Cancer |
2.7% |
| Multiple Sclerosis |
2.7% |
| Pneumonia |
2.6% |
| Urinary Tract Infection |
2.5% |
|
| Secondary |
| Multiple Sclerosis |
56.7% |
| Product Used For Unknown Indication |
8.5% |
| Drug Use For Unknown Indication |
7.1% |
| Relapsing-remitting Multiple Sclerosis |
6.0% |
| Depression |
4.5% |
| Pain |
3.3% |
| Muscle Spasms |
1.8% |
| Foetal Exposure During Pregnancy |
1.7% |
| Multiple Sclerosis Relapse |
1.4% |
| Anxiety |
1.3% |
| Hypertension |
1.2% |
| Off Label Use |
1.0% |
| Bladder Disorder |
0.9% |
| Blood Cholesterol Increased |
0.8% |
| Gait Disturbance |
0.8% |
| Drug Exposure During Pregnancy |
0.7% |
| Nausea |
0.6% |
| Contraception |
0.5% |
| Fatigue |
0.5% |
| Insomnia |
0.5% |
|
| Multiple Sclerosis Relapse |
13.1% |
| Convulsion |
8.9% |
| Overdose |
7.3% |
| Adverse Drug Reaction |
6.8% |
| Urticaria |
6.3% |
| Suicidal Ideation |
5.8% |
| Urinary Tract Infection |
5.8% |
| Vomiting |
5.8% |
| Upper Respiratory Tract Infection |
4.7% |
| Urinary Incontinence |
4.7% |
| Tremor |
4.2% |
| Oesophageal Carcinoma |
3.7% |
| Pyrexia |
3.7% |
| Staphylococcal Infection |
3.1% |
| Weight Increased |
3.1% |
| Drug Exposure During Pregnancy |
2.6% |
| Intervertebral Disc Protrusion |
2.6% |
| Malaise |
2.6% |
| Pain |
2.6% |
| Pulmonary Embolism |
2.6% |
|
| Concomitant |
| Multiple Sclerosis |
58.8% |
| Product Used For Unknown Indication |
17.4% |
| Relapsing-remitting Multiple Sclerosis |
2.9% |
| Pain |
2.8% |
| Depression |
2.6% |
| Gait Disturbance |
2.3% |
| Drug Use For Unknown Indication |
1.3% |
| Headache |
1.3% |
| Anxiety |
1.3% |
| Hypertension |
1.2% |
| Fatigue |
1.1% |
| Smoking Cessation Therapy |
1.1% |
| Osteoporosis |
1.0% |
| Multiple Sclerosis Relapse |
0.8% |
| Migraine |
0.7% |
| Hormone Replacement Therapy |
0.7% |
| Blood Cholesterol Increased |
0.7% |
| Gastrooesophageal Reflux Disease |
0.7% |
| Muscle Spasms |
0.7% |
| Neuralgia |
0.7% |
|
| Multiple Sclerosis Relapse |
15.4% |
| Urinary Tract Infection |
7.1% |
| Drug Ineffective |
6.5% |
| Weight Increased |
5.7% |
| Multiple Sclerosis |
5.6% |
| Vomiting |
5.6% |
| Pain |
5.1% |
| Urticaria |
4.8% |
| Tremor |
4.6% |
| Death |
4.2% |
| Weight Decreased |
4.2% |
| Fatigue |
3.9% |
| Vision Blurred |
3.9% |
| Visual Impairment |
3.9% |
| Convulsion |
3.5% |
| Muscle Spasms |
3.5% |
| Headache |
3.2% |
| Rash |
3.2% |
| Pain In Extremity |
3.1% |
| Pneumonia |
3.1% |
|
| Interacting |
| Multiple Sclerosis |
50.0% |
| Drug Use For Unknown Indication |
8.3% |
| Metastatic Malignant Melanoma |
8.3% |
| Muscle Spasticity |
8.3% |
| Optic Neuritis |
8.3% |
| Pain |
8.3% |
| Smoking Cessation Therapy |
8.3% |
|
| Drug Interaction |
16.7% |
| Hepatic Enzyme Increased |
16.7% |
| Overdose |
16.7% |
| Stress |
16.7% |
| Syncope |
16.7% |
| Transient Ischaemic Attack |
16.7% |
|
